Zoulim F, Capel F, Berthillon P, Trépo C, Petit M A
Service d'Hépato-Gastroentérologie, Hôtel-Dieu, Lyon.
Gastroenterol Clin Biol. 1995 Dec;19(12):970-5.
We performed a prospective study to determine the clinical and virological significance of pre-S antigen detection in serum samples from patients with chronic hepatitis B virus infection. Four hundred thirty seven consecutive serum samples from 116 patients were tested for the presence of both pre-S1 and pre-S2 antigens by radioimmunoassay using specific monoclonal antibodies.
The pre-S1 antigen/HBs antigen ratio, gave an estimation of the number of pre-S1 epitopes expressed on the surface of circulating viral particles, and was positively correlated with the intensity of viral replication intensity (P < 0.05). Moreover, the pre-S1 antigen/HBs antigen ratio was significantly higher in patients suffering from chronic hepatitis associated with viral replication (24% +/- 13); in anti-HBe positive patients, the pre-S1 antigen/HBs antigen ratio was higher in patients replicating a HBe antigen minus variant of the hepatitis B virus and suffering from chronic hepatitis (17% +/- 9) than in asymptomatic HBs antigen carriers (5% +/- 6) (P < 0.05). The pre-S2 antigen/HBs antigen ratio was not correlated with the level of viral replication or with the patient's clinical status.
This study confirms that pre-S1 antigen detection is a reliable marker of hepatitis B virus replication which can be easily performed in chronically infected patients. This assay is especially useful in identifying anti-HBe positive carriers who replicate a minus pre-core mutant and could benefit from antiviral therapy.
我们进行了一项前瞻性研究,以确定慢性乙型肝炎病毒感染患者血清样本中前S抗原检测的临床和病毒学意义。使用特异性单克隆抗体通过放射免疫分析法对116例患者连续采集的437份血清样本检测前S1和前S2抗原的存在情况。
前S1抗原/乙肝表面抗原比值可估算循环病毒颗粒表面表达的前S1表位数量,与病毒复制强度呈正相关(P<0.05)。此外,伴有病毒复制的慢性肝炎患者的前S1抗原/乙肝表面抗原比值显著更高(24%±13);在抗HBe阳性患者中,复制乙肝病毒HBe抗原阴性变异体并患有慢性肝炎的患者的前S1抗原/乙肝表面抗原比值(17%±9)高于无症状乙肝表面抗原携带者(5%±6)(P<0.05)。前S2抗原/乙肝表面抗原比值与病毒复制水平或患者临床状态无关。
本研究证实前S1抗原检测是乙肝病毒复制的可靠标志物,可在慢性感染患者中轻松进行。该检测对于识别复制前核心突变阴性的抗HBe阳性携带者尤其有用,这些携带者可能从抗病毒治疗中获益。